Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Univ CaliforniafiledCriticalPfizer
Publication of AR113854A1publicationCriticalpatent/AR113854A1/en
La presente proporciona anticuerpos y sus fragmentos de unión a antígeno, que específicamente se une con CXCR5. Los anticuerpos pueden ser afucosilados y exhibir mayor ADCC en comparación con los anticuerpos fucosilados por lo demás idénticos. Además incluye usos y métodos asociados de uso de los anticuerpos.The present provides antibodies and their antigen-binding fragments, which specifically bind with CXCR5. Antibodies can be afucosylated and exhibit higher ADCC compared to otherwise identical fucosylated antibodies. It also includes uses and associated methods of using the antibodies.
ARP180103494A2017-12-012018-11-28
ANTI-CXCR5 ANTIBODIES, COMPOSITIONS AND USES THEREOF
AR113854A1
(en)